Receptora | [3H]NMS KD | Methoctramine pKi | SMP pKi | LMP pKi |
---|---|---|---|---|
nM | ||||
M3 wt | 0.32 ± 0.01 | 5.69 ± 0.12 | 4.41 ± 0.15 | 5.43 ± 0.13 |
M2 wt | 0.78 ± 0.04 | 7.29 ± 0.04 | 5.25 ± 0.12 | 6.78 ± 0.08 |
Mutations in o3 of M3 | ||||
M3 S | 0.32 ± 0.02b | 5.95 ± 0.15b,c | 4.58 ± 0.14b | 5.64 ± 0.12 |
M3 K | 0.34 ± 0.02b | 6.49 ± 0.11b,d | 4.96 ± 0.15b,d | 6.15 ± 0.11b,d |
M3 KFN | 0.51 ± 0.03b,d | 6.51 ± 0.09b,d | n.d. | n.d. |
M3 DKFN | 0.49 ± 0.03b,d | 6.51 ± 0.16b,d | n.d. | n.d. |
M3 SK | 0.34 ± 0.02b | 7.02 ± 0.19c,d | 5.33 ± 0.09d | 6.65 ± 0.09d |
M3 SKFN | 0.68 ± 0.05d | 7.04 ± 0.15c,d | n.d. | n.d. |
M3 DSKFN | 0.76 ± 0.05d | 7.17 ± 0.04c,d | 5.20 ± 0.11d | 6.68 ± 0.08d |
Mutations in o3 of M2 | ||||
M2 P | 0.62 ± 0.05b | 6.31 ± 0.12b | n.d. | n.d. |
n.d., not determined.
↵a For the mutants nomenclature, see Materials and Methods and Supplemental Fig. 3.
↵b Significantly different from M2 wt (P < 0.01, multiparametric one-way analysis of variance with Tukey-Kramer post-test).
↵c Significantly different from M3 K (P < 0.01, multiparametric one-way analysis of variance with Tukey-Kramer post-test).
↵d Significantly different from M3 wt (P < 0.01, multiparametric one-way analysis of variance with Tukey-Kramer post-test).